Equity Overview
Price & Market Data
Price: $25.70
Daily Change: -$0.0901 / 0.35%
Range: $24.87 - $26.85
Market Cap: $2,881,335,808
Volume: 3,531,910
Performance Metrics
1 Week: 8.73%
1 Month: -8.29%
3 Months: -26.56%
6 Months: -60.12%
1 Year: -59.81%
YTD: -36.23%
Company Details
Employees: 36
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.